This BioPharma Could Be First To Market With Its Celiac Therapy – Phase 3 Clinical Trials To Commence In 2024

James Sapirstein, Chairman, President & CEO of First Wave BioPharma, Inc. (NASDAQ: FWBI) was recently a guest on Benzinga’s All-Access.

First Wave BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company reports it has several exciting therapies currently undergoing research across many different indications related to GI diseases.

Watch the full interview here:

Featured photo by Hans Reniers on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.